RE:RE:New Press Release - Theratechnologies Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian CancerI read the bad news into Marsolais statement of, oh, hey, by the way, we're still looking for that lifeline in the form of a partner to keep this thing going. All leadership who has put him in a position of having to make a statement like that needs to go. The only way they get that lifeline is if the results are dramatically different, and even still they've lost quite a bit of negotiating leverage.